Granules India Receives AP Status for Metformin Hydrochloride ANDA090564
Granules India has received an Abbreviated New Drug Application (ANDA) approval status for Metformin Hydrochloride.
Published: July 12, 2026
Updated: July 12, 2026
Author: Humanexa Intelligence
Therapeutic area: Diabetes / Oral Hypoglycemic
Asset: Granules
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Asset
Granules
Indication
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
The approval of Granules India's ANDA for Metformin Hydrochloride signifies increased competition in the diabetes treatment market. This could impact pricing and market share dynamics for existing players, necessitating strategic adjustments.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor the launch timeline and market entry strategies of Granules India for Metformin Hydrochloride.
Related companies & assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.